NCT03631043: Phase 1 - Personalized Vaccine in Treating Participants With Smoldering MM
NCT03657251: MMRF CureCloud Research Initiative
NCT03673826: Phase 2: Carfilzomib, Lenalidomide and Dex Versus Lenalidomide and Dex High- Risk SMM
NCT03289299 : Phase 2 - Agg. Smoldering Curative Approach Eval. Novel Therapies & Transplant ASCENT
NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab MGUS / Smoldering Myeloma SMM
NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in HI Risk SMM
NCT03327597 : Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM)
NCT02960555: Phase 2 - Isatuximab in Patients With High Risk Smoldering Plasma Cell Myeloma
NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in SMM
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM
NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High Risk Smoldering MM GEM-CESAR trial
NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS
NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in Hi R SMM
NCT01572480: Phase 2: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
NCT01169337: Phase 3 -Lenalidomide or Observation in Asymptomatic High-Risk Smoldering Myeloma E3A06
NCT00480363: Phase 3: Revlimid / Dex ( ReDex) VS Observation in Smoldering MM (QUIREDEX)